Regulatory

Breakthrough in Genetic Disorder Treatment: GC Pharma’s Sanfilippo Syndrome Drug Receives FDA Phase 1 Approval

로
Sanfilippo,GC Pharma,Regulatory,Treatment,Regulatory

Sanfilippo Syndrome, also known as Mucopolysaccharidosis Type III, is a rare genetic disorder caused by the body’s inability to produce an enzyme necessary for breaking down heparan sulfate. This accumulation leads to severe organ damage and developmental delays. GC Pharma, in collaboration with biotech firm Nobel Pharma, has announced that their innovative treatment for Sanfilippo … 더 읽기

South Korea Advances Regulation on Illegal Content Distribution by CDN Providers

로

The South Korean Broadcasting and Telecommunications Commission (KCC) is pushing forward with amendments to the enforcement decree under the Act on Promotion of Information and Communications Network Utilization and Information Protection, etc. This legislative movement comes as a strategic follow-up to the legal provisions established in January, mandating content delivery network (CDN) providers to implement … 더 읽기